Adherence of cell-free DNA noninvasive prenatal screens to ACMG recommendations

Brian G. Skotko, Megan A. Allyse, Komal Bajaj, Robert G. Best, Susan D. Klugman, Mark Leach, Stephanie Meredith, Marsha Michie, Katie Stoll, Anthony R. Gregg

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: Noninvasive prenatal screening (NIPS) for fetal aneuploidy via cell-free DNA has been commercially available in the United States since 2011. In 2016, the American College of Medical Genetics and Genomics (ACMG) issued a position statement with specific recommendations for testing laboratories. We sought to evaluate adherence to these recommendations. Methods: We focused on commercial laboratories performing NIPS testing in the United States as of 1 January 2018. Sample laboratory reports and other materials were scored for compliance with ACMG recommendations. Variables scored for common and sex chromosome aneuploidy detection included detection rate, specificity, positive and negative predictive value, and fetal fraction. Labs that performed analysis of copy-number variants and results for aneuploidies other than those commonly reported were identified. Available patient education materials were similarly evaluated. Results: Nine of 10 companies reported fetal fraction in their reports, and 8 of 10 did not offer screening for autosomal aneuploidies beyond trisomy 13, 18, and 21. There was inconsistency in the application and reporting of other measures recommended by ACMG. Conclusions: Laboratories varied in the degree to which they met ACMG position statement recommendations. No company adhered to all laboratory guidance.

Original languageEnglish (US)
JournalGenetics in Medicine
DOIs
StatePublished - Jan 1 2019

Fingerprint

Medical Genetics
Genomics
Aneuploidy
DNA
Prenatal Diagnosis
Sex Chromosomes
Patient Education
Down Syndrome

Keywords

  • NIPS
  • NIPT
  • noninvasive prenatal screens
  • noninvasive prenatal tests
  • trisomy 21

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Adherence of cell-free DNA noninvasive prenatal screens to ACMG recommendations. / Skotko, Brian G.; Allyse, Megan A.; Bajaj, Komal; Best, Robert G.; Klugman, Susan D.; Leach, Mark; Meredith, Stephanie; Michie, Marsha; Stoll, Katie; Gregg, Anthony R.

In: Genetics in Medicine, 01.01.2019.

Research output: Contribution to journalArticle

Skotko, BG, Allyse, MA, Bajaj, K, Best, RG, Klugman, SD, Leach, M, Meredith, S, Michie, M, Stoll, K & Gregg, AR 2019, 'Adherence of cell-free DNA noninvasive prenatal screens to ACMG recommendations', Genetics in Medicine. https://doi.org/10.1038/s41436-019-0485-2
Skotko, Brian G. ; Allyse, Megan A. ; Bajaj, Komal ; Best, Robert G. ; Klugman, Susan D. ; Leach, Mark ; Meredith, Stephanie ; Michie, Marsha ; Stoll, Katie ; Gregg, Anthony R. / Adherence of cell-free DNA noninvasive prenatal screens to ACMG recommendations. In: Genetics in Medicine. 2019.
@article{7558ea16a3364a1f9b09d2954fa8e394,
title = "Adherence of cell-free DNA noninvasive prenatal screens to ACMG recommendations",
abstract = "Purpose: Noninvasive prenatal screening (NIPS) for fetal aneuploidy via cell-free DNA has been commercially available in the United States since 2011. In 2016, the American College of Medical Genetics and Genomics (ACMG) issued a position statement with specific recommendations for testing laboratories. We sought to evaluate adherence to these recommendations. Methods: We focused on commercial laboratories performing NIPS testing in the United States as of 1 January 2018. Sample laboratory reports and other materials were scored for compliance with ACMG recommendations. Variables scored for common and sex chromosome aneuploidy detection included detection rate, specificity, positive and negative predictive value, and fetal fraction. Labs that performed analysis of copy-number variants and results for aneuploidies other than those commonly reported were identified. Available patient education materials were similarly evaluated. Results: Nine of 10 companies reported fetal fraction in their reports, and 8 of 10 did not offer screening for autosomal aneuploidies beyond trisomy 13, 18, and 21. There was inconsistency in the application and reporting of other measures recommended by ACMG. Conclusions: Laboratories varied in the degree to which they met ACMG position statement recommendations. No company adhered to all laboratory guidance.",
keywords = "NIPS, NIPT, noninvasive prenatal screens, noninvasive prenatal tests, trisomy 21",
author = "Skotko, {Brian G.} and Allyse, {Megan A.} and Komal Bajaj and Best, {Robert G.} and Klugman, {Susan D.} and Mark Leach and Stephanie Meredith and Marsha Michie and Katie Stoll and Gregg, {Anthony R.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41436-019-0485-2",
language = "English (US)",
journal = "Genetics in Medicine",
issn = "1098-3600",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Adherence of cell-free DNA noninvasive prenatal screens to ACMG recommendations

AU - Skotko, Brian G.

AU - Allyse, Megan A.

AU - Bajaj, Komal

AU - Best, Robert G.

AU - Klugman, Susan D.

AU - Leach, Mark

AU - Meredith, Stephanie

AU - Michie, Marsha

AU - Stoll, Katie

AU - Gregg, Anthony R.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: Noninvasive prenatal screening (NIPS) for fetal aneuploidy via cell-free DNA has been commercially available in the United States since 2011. In 2016, the American College of Medical Genetics and Genomics (ACMG) issued a position statement with specific recommendations for testing laboratories. We sought to evaluate adherence to these recommendations. Methods: We focused on commercial laboratories performing NIPS testing in the United States as of 1 January 2018. Sample laboratory reports and other materials were scored for compliance with ACMG recommendations. Variables scored for common and sex chromosome aneuploidy detection included detection rate, specificity, positive and negative predictive value, and fetal fraction. Labs that performed analysis of copy-number variants and results for aneuploidies other than those commonly reported were identified. Available patient education materials were similarly evaluated. Results: Nine of 10 companies reported fetal fraction in their reports, and 8 of 10 did not offer screening for autosomal aneuploidies beyond trisomy 13, 18, and 21. There was inconsistency in the application and reporting of other measures recommended by ACMG. Conclusions: Laboratories varied in the degree to which they met ACMG position statement recommendations. No company adhered to all laboratory guidance.

AB - Purpose: Noninvasive prenatal screening (NIPS) for fetal aneuploidy via cell-free DNA has been commercially available in the United States since 2011. In 2016, the American College of Medical Genetics and Genomics (ACMG) issued a position statement with specific recommendations for testing laboratories. We sought to evaluate adherence to these recommendations. Methods: We focused on commercial laboratories performing NIPS testing in the United States as of 1 January 2018. Sample laboratory reports and other materials were scored for compliance with ACMG recommendations. Variables scored for common and sex chromosome aneuploidy detection included detection rate, specificity, positive and negative predictive value, and fetal fraction. Labs that performed analysis of copy-number variants and results for aneuploidies other than those commonly reported were identified. Available patient education materials were similarly evaluated. Results: Nine of 10 companies reported fetal fraction in their reports, and 8 of 10 did not offer screening for autosomal aneuploidies beyond trisomy 13, 18, and 21. There was inconsistency in the application and reporting of other measures recommended by ACMG. Conclusions: Laboratories varied in the degree to which they met ACMG position statement recommendations. No company adhered to all laboratory guidance.

KW - NIPS

KW - NIPT

KW - noninvasive prenatal screens

KW - noninvasive prenatal tests

KW - trisomy 21

UR - http://www.scopus.com/inward/record.url?scp=85063792766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063792766&partnerID=8YFLogxK

U2 - 10.1038/s41436-019-0485-2

DO - 10.1038/s41436-019-0485-2

M3 - Article

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

ER -